Rallybio (RLYB) Stock Price, News & Analysis

Company Overview

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Key Stats

• Today's Range: $1.06 to $1.12
• 50-Day Range: $0.99 to $1.17
• 52-Week Range: $0.96 to $3.46
• Volume: 118,489 shs
• Average Volume: 576,037 shs
• Market Capitalization: $46.05 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.75
• Consensus Rating: Moderate Buy

Rallybio Stock Analysis - MarketRank™

Rallybio scored higher than 64% of companies evaluated by MarketBeat, and ranked 430th out of 986 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Rallybio has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Rallybio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Rallybio are expected to grow in the coming year, from ($1.45) to ($1.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rallybio is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rallybio is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rallybio has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.30% of the float of Rallybio has been sold short.

Short Interest Ratio / Days to Cover

Rallybio has a short interest ratio ("days to cover") of 6.5.

Change versus previous month

Short interest in Rallybio has recently decreased by 13.64%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rallybio does not currently pay a dividend.

Dividend Growth

Rallybio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.30% of the float of Rallybio has been sold short.

Short Interest Ratio / Days to Cover

Rallybio has a short interest ratio ("days to cover") of 6.5.

Change versus previous month

Short interest in Rallybio has recently decreased by 13.64%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.42

News Sentiment

Rallybio has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Rallybio this week, compared to 1 article on an average week.

MarketBeat Follows

Only 1 people have added Rallybio to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rallybio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.40% of the stock of Rallybio is held by insiders.

Percentage Held by Institutions

90.34% of the stock of Rallybio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RLYB Stock Analysis - Frequently Asked Questions

How have RLYB shares performed this year?

Rallybio's stock was trading at $2.39 at the beginning of the year. Since then, RLYB stock has decreased by 53.6% and is now trading at $1.11.
View the best growth stocks for 2024 here.

How were Rallybio's earnings last quarter?

Rallybio Co. (NASDAQ:RLYB) released its quarterly earnings data on Thursday, August, 8th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.05. The firm had revenue of $0.30 million for the quarter.

When did Rallybio IPO?

Rallybio (RLYB) raised $80 million in an initial public offering (IPO) on Thursday, July 29th 2021. The company issued 5,750,000 shares at $13.00-$15.00 per share.

Who are Rallybio's major shareholders?

Top institutional shareholders of Rallybio include Canaan Partners XI LLC (4.61%). Insiders that own company stock include Kush Parmar, Jonathan I Lieber, Opportunities I LP 5Am, Martin Mackay, Stephen Uden and Jeffrey M Fryer.
View institutional ownership trends.

How do I buy shares of Rallybio?

Shares of RLYB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Rallybio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rallybio investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Plug Power (PLUG).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 11/12/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/11/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RLYB
• CUSIP: N/A
• CIK: 1739410
• Web: www.rallybio.com
• Phone: 203-59-3820
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.75
• High Stock Price Target: $15.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +778.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-74,560,000.00
• Net Margins: N/A
• Pretax Margin: -23,895.65%
• Return on Equity: -72.97%
• Return on Assets: -65.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.52
• Quick Ratio: 7.52

Sales & Book Value

• Annual Sales: $299,000.00
• Price / Sales: 154.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.81 per share
• Price / Book: 0.40

Miscellaneous

• Outstanding Shares: 41,488,000
• Free Float: 38,418,000
• Market Cap: $46.05 million
• Optionable: Not Optionable
• Beta: -1.67